I think MM's and shorts have had AMRN stock figured out for years. They know the patterns, they know the volume, and they just keep riding it for profit.
Until there is significantly more demand on the stock, we will just continue to ride the lows. Sarissa shrinking the float can help, but adding 1% doesn't really do anything. We're still only around 30% institutional ownership, which is quite low for a biotech.
If Sarissa keeps buying, that could encourage more institutions to jump on board.
Retail is non-existent in terms of additional purchases.